¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lymphocyte proliferation test2"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® lymphocyte ÇÑ±Û ¸²ÇÁ±¸
¼³¸í   
  ¸é¿ª±â´ÉÀ» ´ã´çÇϴ ¼¼Æ÷. °ñ¼ö¿¡¼­ ¸¸µé¾îÁö¸ç, ¸²ÇÁ±¸´Â Å©°Ô 2°¡Áö·Î ´ëºÐµÈ´Ù. À̸¥¹Ù T¸²ÇÁ¼¼Æ÷, B¸²ÇÁ¼¼Æ÷·Î ³ª´µ¾îÁö°Ô µÈ´Ù. T¸²ÇÁ¼¼Æ÷´Â ¼¼Æ÷¼º¸é¿ª¿¡ °ü¿©Çϸç, ÁַΠ¹ÙÀÌ·¯½ºº´¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ̳ª, ¾Ë·¹¸£±â(¸é¿ª¹ÝÀÀ 4¹øÇü µî) µî¿¡ °ü¿©ÇÑ´Ù. ÀÌ¿¡ ºñÇØ B¸²ÇÁ¼¼Æ÷´Â Ã¼¾×¼º¸é¿ª¿¡ °ü¿©ÇÏ¿©, Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Ç×ü¸¦ »ý»êÇϰí ÁַΠ¼¼±Õ°¨¿°¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ» ´ã´çÇÑ´Ù.
¿µ¹® T-lymphocyte ÇÑ±Û Æ¼ ¸²ÇÁ±¸
¼³¸í   
  ¸²ÇÁ°è¼¼Æ÷(¸²ÇÁ±¸)´Â Å©°Ô 2°¡Áö·Î ´ëºÐµÈ´Ù. À̸¥¹Ù T¸²ÇÁ¼¼Æ÷(T-cell), B¸²ÇÁ¼¼Æ÷(B-cell)·Î ³ª´µ¾îÁø´Ù. T¸²ÇÁ¼¼Æ÷´Â ¼¼Æ÷¼º ¸é¿ª¿¡ °ü¿©Çϸç, ÁַΠ¹ÙÀÌ·¯½ºº´¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ̳ª, ¾Ë·¹¸£±â µî¿¡ °ü¿©ÇÑ´Ù. ÀÌ¿¡ ºñÇØ B¸²ÇÁ¼¼Æ÷´Â Ã¼¾×¼º ¸é¿ª¿¡ °ü¿©ÇÏ¿©, Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Ç×ü¸¦ »ý»êÇϰí ÁַΠ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±â´ÉÀ» ´ã´çÇÑ´Ù. T-¸²ÇÁ±¸´Â ¸é¿ª±â´É¿¡ °¡Àå Áß¿äÇÑ ¿ªÇÒÀ» Çϴ ¼¼Æ÷·Î¼­ ¼¼Æ÷¸é¿ªÀ» ´ã´çÇϸç B-cellÀÇ ÀÛ¿ëÀ» Á¶ÀýÇϴ ±â´Éµµ ÀÖ´Ù. °ñ¼ö¿¡¼­ »ý¼ºµÇ¾î °¡½¿»ù¿¡¼­ ¼º¼÷µÈ´Ù. Å©°Ô º¸Á¶T¼¼Æ÷(helper T-cell: ¸é¿ªÀÛ¿ëÀÇ ¹ß»ýÀ» º¸Á¶ÇÑ´Ù)¿Í T¼¼Æ÷(suppressor T-cell: ¸é¿ªÀÛ¿ëÀÇ ¹ß»ýÀ» ¾ïÁ¦ÇÑ´Ù)·Î ±¸ºÐµÇ¸ç À̵éÀº ¼¼Æ÷ Ç¥¸é¿¡ ºÐÆ÷Çϴ Ç׿ø¿¡ ÀÇÇØ¼­ ½Äº°µÉ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • anterior hyaloid fibrovascular proliferation
    ¾ÕÀ¯¸®Ã¼¼¶À¯Ç÷°üÁõ½Ä
  • proliferation
    Áõ½Ä
  • proliferation zone
    Áõ½ÄÃþ
  • pseudoepitheliomatous proliferation
    °ÅÁþ»óÇÇÁ¾¼ºÁõ½Ä
  • pseudosarcomatous proliferation
    °ÅÁþÀ°Á¾Áõ½Ä, °¡¼ºÀ°Á¾Áõ½Ä
  • atypical lymphocyte
    ºñÁ¤Çü¸²ÇÁ±¸
  • effector lymphocyte
    È¿°ú¸²ÇÁ±¸
  • killer lymphocyte
    »ìÇØ¸²ÇÁ±¸, ¼¼Æ÷µ¶¼º¸²ÇÁ±¸
  • lymphocyte
    ¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤ÀÎÀÚ
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç
  • mixed lymphocyte culture test
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • proliferation
    Áõ½Ä
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç
  • lymphocyte
    ¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • anterior hyaloid fibrovascular proliferation
    ¾ÕÀ¯¸®Ã¼¼¶À¯Ç÷°üÁõ½Ä
  • proliferation
    Áõ½Ä
  • proliferation zone
    Áõ½ÄÃþ
  • pseudoepitheliomatous proliferation
    °ÅÁþ»óÇÇÁ¾¼ºÁõ½Ä
  • pseudosarcomatous proliferation
    °ÅÁþÀ°Á¾¼ºÁõ½Ä, °¡¼ºÀ°Á¾Áõ½Ä
  • atypical lymphocyte
    ºñÀüÇü¸²ÇÁ±¸
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤±â
  • effector lymphocyte
    ÀÛµ¿¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • killer lymphocyte
    ¼¼Æ÷µ¶¼º¸²ÇÁ±¸
  • lymphocyte
    ¸²ÇÁ±¸
  • leukocytoid lymphocyte
    ¹éÇ÷±¸¸ð¾ç¸²ÇÁ±¸
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • primed lymphocyte
    ÃÊȸ¹Î°¨¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • T cell ; T lymphocyte ; thymus derived lymphocyte
    T¼¼Æ÷ ; T¸²ÇÁ? ; Èä¼±À¯·¡¸²ÇÁ?
  • anterior hyaloid fibrovascular proliferation
    ¾ÕÀ¯¸®Ã¼¼¶À¯Ç÷°üÁõ½Ä
  • proliferation phase
    Áõ½Ä±â(ñòãÖÑ¢).
  • proliferation zone
    Áõ½ÄÃþ
  • reactive pseudosarcomatous proliferation
    ¹ÝÀÀ¼º °¡¼ºÀ°Á¾¼º Áõ½Ä(¡­Ê£àõë¿ðþàõ)
  • B cell/lymphocyte
    B ¼¼Æ÷/¸²ÇÁ±¸
  • B lymphocyte
    B ¸²ÇÁ±¸
  • B-lymphocyte
    B ¸²ÇÁ±¸.
  • Bare lymphocyte syndrome
    ¹«Ç¥Áö¸²ÇÁ±¸ÁõÈıº
  • T cell/lymphocyte
    T ¼¼Æ÷/¸²ÇÁ±¸
  • T lymphocyte
    T ¸²ÇÁ±¸
  • T-lymphocyte
    T-Àӯı¸
  • anti-lymphocyte globulin
    ¸²ÇÁ±¸ Çױ۷κҸ°
  • antigen, lymphocyte defined (LD)
    ¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
  • granulocyte-monocyte-lymphocyte antigens
    °ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte proliferation
    ¸²ÇÁ±¸Áõ½Ä
  • anterior hyaloid fibrovascular proliferation
    ¾ÕÀ¯¸®Ã¼¼¶À¯Ç÷°üÁõ½Ä
  • atherosclerosis,intimal smooth muscle proliferation
    ³»¸·ÆòȰ±Ù Áõ½Ä(ҮدøÁüÀÐÉñòãÖ)
  • cell proliferation
    ¼¼Æ÷ Áõ½Ä
  • cell,proliferation
    Áõ½Ä(ñòãÖ)
  • massive periretinal proliferation<¿¾>=>PVR
    Áõ½ÄÀ¯¸®Ã¼¸Á¸·º´Áõ
  • nuclear proliferation =nucleosis
    ÇÙÁõ½Ä(ú·ñòãÖ).
  • proliferation phase
    Áõ½Ä±â(ñòãÖÑ¢).
  • proliferation zone
    Áõ½ÄÃþ
  • pseudoepitheliomatous proliferation
    °¡¼º»óÇÇÁ¾¼º Áõ½Ä
  • pseudosarcomatous proliferation
    °¡¼ºÀ°Á¾¼º Áõ½Ä(Ê£àõë¿ðþàõ ñòãÖ)
  • reactive pseudosarcomatous proliferation
    ¹ÝÀÀ¼º °¡¼ºÀ°Á¾¼º Áõ½Ä(¡­Ê£àõë¿ðþàõ)
  • zone of proliferation
    Áõ½ÄÃþ, Áõ½Ä´ë (ñòãÖÓá).
  • anti-lymphocyte globulin
    ¸²ÇÁ±¸ Çױ۷κҸ°
  • antigen, lymphocyte defined (LD)
    ¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Proliferation zone
    Áõ½ÄÃþ
    [¿¾ ¿ë¾î] Áõ½Ä´ë
  • Small lymphocyte
    ÀÛÀº¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ¼ÒÀӯı¸
  • Large lymphocyte
    Å«¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ´ëÀӯı¸
  • Medium-sized lymphocyte
    Áß°£¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ÁßÀӯı¸
  • Lymphocyte
    ¸²ÇÁ±¸
    [¿¾ ¿ë¾î] Àӯı¸
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸-À¯µµ(ë¯Óô) È­ÇÐÁÖ¼ºÀÎÀÚ(ûùùÊñËà÷ì×í­)
  • lymphocyte transformation
    ¸²ÇÁ±¸º¯Çü(ܨû¡)
  • mixed lymphocyte culture
    È¥ÇÕ(ûèùê)¸²ÆÄ±¸¹è¾ç(ÛÆå×)
  • small lymphocyte
    ¼Ò(á³)Àӯı¸
  • T lymphocyte
    T Àӯı¸
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • proliferation
    Áõ½Ä, ¹ø½Ä
  • lymphocyte
    ¸²ÇÁ±¸
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • T lymphocyte
    T¸²ÇÁ±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MILP mitogen-induced lymphocyte proliferation
CTL cervico-thoraco-lumbar; control; cytolytic C lymphocyte; cytotoxic T-lymphocyte
HLA-LD human lymphocyte antigen-lymphocyte defined
LD labor and delivery; laboratory data; labyrinthine defect; lactate dehydrogenase; laser Doppler; lear...
MLC minimum lethal concentration; mixed leukocyte culture; mixed ligand chelate; mixed lymphocyte concen...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LPT Lymphocyte Proliferation Test
LP Lymphocyte proliferation
MPP Massive periretinal proliferation
PCNA Proliferation Cell Nuclear Antigen
PI Proliferation Index
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bone proliferation
    °ñ Áõ½Ä
  • proliferation phase
    Áõ½Ä±â
  • pseudosarcomatous proliferation
    °¡¼º À°Á¾¼º Áõ½Ä
  • B lymphocyte
    B ¸²ÇÁ±¸
    1. Èä¼± ºñÀÇÁ¸¼ºÀ¸·Î Èä¼±ÀÇ ¿µÇâÀ» ¹ÞÁö ¾Ê°í, Á¶Á÷À» À¯ÁÖÇÏ´Â ¸²ÇÁ±¸. ü¾×¼º ¸é¿ª¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Ç׿ø¿¡ ÀÇÇÑ ÀÚ±ØÀ¸·Î ¾×¼º Ç×ü¸¦ ÇÕ¼ºÇÏ´Â ÇüÁú±¸·Î µÈ´Ù. 2. Ç÷¾×, °ñ¼ö ¹× ¸²ÇÁÀý, ºñÀå, Æíµµ µî ¸²ÇÁÁ¶Á÷, ±×¸®°í ¼ÒÈ­°ü°è µîÀÇ ºñ¸²ÇÁ Á¶Á÷¿¡ ºÐÆ÷ÇÑ´Ù. ÀÎü Ç÷¾×ÀÇ 10-20% Â÷ÁöÇÑ´Ù. Ç׿ø µî¿¡ ÀÇÇØ Ȱ¼ºÈ­µÇ¸é ¸²ÇÁ¿©Æ÷ ³»¿¡¼­ ¸ð¼¼Æ÷ º¯È¯
  • B-lymphocyte
    B ¸²ÇÁ±¸
    Ç÷Áß Àӯı¸ÀÇ 5-15%¸¦ Â÷ÁöÇÏ¸ç ¼¼Æ÷ Ç¥¸é¿¡ ¸é¿ª ±Û·ÎºÎ¸°ÀÌ Á¸ÀçÇÑ´Ù. ÀÌµé ¸é¿ª ±Û·ÎºÎ¸°Àº Ç׿ø¿¡ ´ëÇÑ ¼ö¿ëü·Î ÀÛ¿ëÇÑ´Ù. Ç÷Áß B ¼¼Æ÷ÀÇ ´ëºÎºÐÀº Ç¥¸é¿¡ IgM°ú IgD¸¦ °®°í ÀÖÀ¸¸ç ¼Ò¼ö¿¡¼­ IgG, IgA ȤÀº IgE°¡ ¹ß°ßµÈ´Ù. ±×·¯³ª Á¡¸· µî¿¡¼­´Â IgA¸¦ °®°í ÀÖ´Â B¼¼Æ÷°¡ ¸¹ÀÌ ¹ß°ßµÈ´Ù.
  • bone marrow-derived lymphocyte
    °ñ¼ö À¯·¡ Àӯı¸
  • bursa-derived lymphocyte
    ÆÄºÎ¸®½Ã¿ì½º ³¶ À¯·¡ Àӯı¸
  • effector lymphocyte
    ÀÛµ¿ ¸²ÇÁ±¸
  • immunocompetent T lymphocyte
    ¸é¿ª Àû°Ý T Àӯı¸
  • lymphocyte
    Àӯı¸
  • lymphocyte defined antigen
    ¸²ÇÁ±¸ ±ÔÁ¤ Ç׿ø
  • lymphocyte migration
    Àӯı¸ À̵¿
  • marrow lymphocyte
    °ñ¼ö ¸²ÇÁ±¸
  • mixed lymphocyte culture
    È¥ÇÕ ¸²ÇÁ±¸ ¹è¾ç
  • monocyte lymphocyte ratio
    ´Ü±¸ ¸²ÇÁ±¸ºñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
lymphocyte lymphocyte A type of non-granular antibodies.
(09 Oct 1997)
gingival proliferation Non-inflammatory enlargement of the gingivae produced by factors other than local irritation. It is characteristically due to an increase in the number of cells.
(12 Dec 1998)
regulatory cell proliferation kinase <enzyme> Involved in mitosis regulation; has characteristics of serine/threonine and tyrosine kinases; isolated from saccharomyces cerevisiae; genbank l08909
Registry number: EC 2.7.1.-
Synonym: rpk1 protein, rpk1 gene product
(26 Jun 1999)
cell proliferation <cell biology> Increase in cell number by division.
(26 Mar 1998)
proliferation <cell biology> The reproduction or multiplication of similar forms, especially of cells and morbid cysts.
Origin: L. Proles = offspring, ferre = to bear
(18 Nov 1997)
proliferation cyst A mother cyst containing daughter cyst's; a cyst with tumourous formation at one portion of the sac.
(05 Mar 2000)
proliferation therapy Rehabilitation of an incompetent structure (ligament or tendon) by the induced proliferation of new cells; accomplished by injecting an irritating substance into the loose ligament or tendon, the resulting scar formation and contracture serving to tighten up the ligament or tendon as scar tissue proliferates.
(05 Mar 2000)
diffuse mesangial proliferation <nephrology, pathology> Inflammation of the kidney glomerulus (blood filtering portion of the kidney) due to the abnormal deposition of IgM antibody in the mesangium layer of the glomerular capillary. A form of glomerulonephritis that appears to be caused by an abnormal immune response. This disorder generally manifests as nephrotic syndrome.
Symptoms include swelling, dark urine, weight gain, hypertension, anorexia and bloody urine.
Acronym: MPGN
(05 Jan 1998)
antigens, differentiation, b-lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumours of B-cell origin.
(12 Dec 1998)
antigens, differentiation, t-lymphocyte Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
(12 Dec 1998)
bare lymphocyte syndrome <syndrome> Absence of HLA antigens on peripheral mononuclear cells, which may result in immunodeficiency.
(05 Mar 2000)
B lymphocyte <haematology, immunology> An immunologically important lymphocyte, produced by the bone marrow, that is responsible for the production of immunoglobulins, it is the precursor of the plasma cell.
The surface markers can be used to detect and differentiate chronic lymphocytic leukaemia from acute lymphocytic leukaemia.
(13 Nov 1997)
b-lymphocyte subsets A classification of B-lymphocytes based on structurally or functionally different populations of cells.
(12 Dec 1998)
gene rearrangement, b-lymphocyte Ordered rearrangement of b-lymphocyte variable gene regions coding for the immunoglobulin chains, thereby contributing to antibody diversity. It occurs during the differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, b-lymphocyte, heavy chain Ordered rearrangement of b-lymphocyte variable gene regions thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the immature b-lymphocyte.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte
    ¸²ÇÁÅç(¼¼Æ÷)
  • proliferation
    ºÐ¾Æ(ºÐ¿­) Áõ½Ä;°ÝÁõ;±ÞÁõ;È®»ên
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á